Currently, there is a steady increase in the prevalence of chronic heart failure (CHF), as well as a high mortality rate associated with this condition, despite the implementation of rational pharmacotherapy. The use of quadrotherapy in clinical practice for the treatment of CHF contributes to the blocking of neurohumoral regulation by inhibiting the renin-angiotensin-aldosterone and sympathoadrenal systems, which leads to decrease in preand afterload and, respectively, to delayed and partial reverse remodeling of the heart chambers. However, these drugs don’t affect the energy metabolism of cardiomyocytes, which is still impaired in patients at the preclinical stage of CHF. In this regard, an important task of practical healthcare is the search for new schemes of a pathogenetic therapy of CHF. One of the promising directions is an adjuvant therapy, which is represented by phosphocreatine, a drug with a cardioprotective effect, proven in a large number of studies, which ensures the maintenance of myocardial energy metabolism. The use of phosphocreatin prevents further deterioration of the contractile function of the heart in patients with CHF, reduces the degree of damage to the cell membrane, improves microcirculation, and also has antiarrhythmic activity, which is especially significant in patients with a history of myocardial infarction. The drug not only improves the quality of life of patients by reducing the severity of symptoms, but also has been proven to increase myocardial contractility and reduce mortality. The purpose of the clinical case report is the description of adjuvant therapy results in a patient with CHF after using all pharmacotherapy reserves. The clinical case demonstrates the effectiveness of CHF treatment with phosphocreatine, confirmed by data from clinical, laboratory and instrumental examinations.